Outstanding response predictions for BRAF/MEK inhibitors are preferentially enriched in melanoma cell lines, while other drugs such as EGFR inhibitors exhibit cancer-type agnostic iGenSig scores, consistent with the tumor-type related clinical activities of these drugs. This evidence concerns the gene EGFR and neoplasm.